<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">GFI1 36N as a therapeutic and prognostic marker for myelodysplastic syndrome</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Lacramioara</forename><surname>Botezatu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lars</forename><forename type="middle">C</forename><surname>Michel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hideki</forename><surname>Makishima</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Translational Hematology and Oncology Research</orgName>
								<orgName type="institution">Taussig Cancer Institute</orgName>
								<address>
									<settlement>Cleveland</settlement>
									<region>OH</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Schroeder</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<orgName type="institution">University Hospital D€ usseldorf</orgName>
								<address>
									<addrLine>D€ usseldorf</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulrich</forename><surname>Germing</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<orgName type="institution">University Hospital D€ usseldorf</orgName>
								<address>
									<addrLine>D€ usseldorf</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rainer</forename><surname>Haas</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<orgName type="institution">University Hospital D€ usseldorf</orgName>
								<address>
									<addrLine>D€ usseldorf</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bert</forename><surname>Van Der Reijden</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Laboratory Medicine</orgName>
								<orgName type="institution">Radboud University Nijmegen Medical Centre</orgName>
								<address>
									<settlement>Nijmegen</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anne</forename><forename type="middle">E</forename><surname>Marneth</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Laboratory Medicine</orgName>
								<orgName type="institution">Radboud University Nijmegen Medical Centre</orgName>
								<address>
									<settlement>Nijmegen</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Saskia</forename><forename type="middle">M</forename><surname>Bergevoet</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Laboratory Medicine</orgName>
								<orgName type="institution">Radboud University Nijmegen Medical Centre</orgName>
								<address>
									<settlement>Nijmegen</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joop</forename><forename type="middle">H</forename><surname>Jansen</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Laboratory Medicine</orgName>
								<orgName type="institution">Radboud University Nijmegen Medical Centre</orgName>
								<address>
									<settlement>Nijmegen</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bartlomiej</forename><surname>Przychodzen</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Translational Hematology and Oncology Research</orgName>
								<orgName type="institution">Taussig Cancer Institute</orgName>
								<address>
									<settlement>Cleveland</settlement>
									<region>OH</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marcin</forename><surname>Wlodarski</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Division of Pediatric Hematology and Oncology</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics and Adolescent Medicine</orgName>
								<orgName type="institution">University of Freiburg</orgName>
								<address>
									<settlement>Freiburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Charlotte</forename><surname>Niemeyer</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Division of Pediatric Hematology and Oncology</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics and Adolescent Medicine</orgName>
								<orgName type="institution">University of Freiburg</orgName>
								<address>
									<settlement>Freiburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Uwe</forename><surname>Platzbecker</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="institution">University Hospital TU</orgName>
								<address>
									<settlement>Dresden, Dresden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gerhard</forename><surname>Ehninger</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="institution">University Hospital TU</orgName>
								<address>
									<settlement>Dresden, Dresden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ashwin</forename><surname>Unnikrishnan</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Lowy Cancer Research Centre and Prince of Wales Clinical School</orgName>
								<orgName type="institution">University of New South Wales</orgName>
								<address>
									<settlement>Sydney</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dominik</forename><surname>Beck</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Lowy Cancer Research Centre and Prince of Wales Clinical School</orgName>
								<orgName type="institution">University of New South Wales</orgName>
								<address>
									<settlement>Sydney</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">John</forename><surname>Pimanda</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Lowy Cancer Research Centre and Prince of Wales Clinical School</orgName>
								<orgName type="institution">University of New South Wales</orgName>
								<address>
									<settlement>Sydney</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eva</forename><surname>Hellstr€ Om-Lindberg</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Center for Hematology and Regenerative Medicine</orgName>
								<orgName type="institution">Karolinska University Hospital Huddinge</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Luca</forename><surname>Malcovati</surname></persName>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Department of Molecular Medicine</orgName>
								<orgName type="department" key="dep2">Department of Hematology Oncology</orgName>
								<orgName type="institution" key="instit1">University of Pavia</orgName>
								<orgName type="institution" key="instit2">Fondazione IRCCS Policlinico San Matteo</orgName>
								<address>
									<settlement>Pavia</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jacqueline</forename><surname>Boultwood</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="laboratory">Nuffield Division of Clinical Laboratory Sciences</orgName>
								<orgName type="institution">University of Oxford</orgName>
								<address>
									<settlement>Radcliffe, Oxford</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andrea</forename><surname>Pellagatti</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="laboratory">Nuffield Division of Clinical Laboratory Sciences</orgName>
								<orgName type="institution">University of Oxford</orgName>
								<address>
									<settlement>Radcliffe, Oxford</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elli</forename><surname>Papaemmanuil</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Cancer Genome Project</orgName>
								<orgName type="institution">Wellcome Trust Sanger Institute</orgName>
								<address>
									<settlement>Hinxton, Cambridge</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Philipp</forename><surname>Le Coutre</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Medical Department with Focus on Hematology/Oncology Charite Berlin</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jaspal</forename><surname>Kaeda</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Medical Department with Focus on Hematology/Oncology Charite Berlin</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bertram</forename><surname>Opalka</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tarik</forename><surname>M€</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Infectiologie et Immunologie</orgName>
								<orgName type="laboratory">Institut de Recherches Cliniques de Montr eal (IRCM), Hematopoiesis and Cancer Research Unit, and D epartement de Microbiologie</orgName>
								<orgName type="institution">Universit e de Montr eal</orgName>
								<address>
									<addrLine>Montr eal</addrLine>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulrich</forename><surname>D€ Uhrsen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jaroslaw</forename><surname>Maciejewski</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Translational Hematology and Oncology Research</orgName>
								<orgName type="institution">Taussig Cancer Institute</orgName>
								<address>
									<settlement>Cleveland</settlement>
									<region>OH</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Cyrus</forename><surname>Khandanpour</surname></persName>
							<email>cyrus.khandanpour@uk-essen.de</email>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Hematology</orgName>
								<orgName type="department" key="dep2">West German Cancer Center</orgName>
								<orgName type="institution" key="instit1">University Hospital Essen</orgName>
								<orgName type="institution" key="instit2">University Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff13">
								<orgName type="department">Department of Hematology</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff14">
								<orgName type="department">West German Cancer Center</orgName>
								<orgName type="institution">University Hospital Essen</orgName>
								<address>
									<postCode>45147</postCode>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">GFI1 36N as a therapeutic and prognostic marker for myelodysplastic syndrome</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">90B186E1DAFBE2EC8F5DAEBAA4A4514C</idno>
					<idno type="DOI">10.1016/j.exphem.2016.04.001</idno>
					<note type="submission">Received 25 February 2016; revised 31 March 2016; accepted 3 April 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:25+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Inherited gene variants play an important role in malignant diseases.</s><s>The transcriptional repressor growth factor independence 1 (GFI1) regulates hematopoietic stem cell (HSC) self-renewal and differentiation.</s><s>A single-nucleotide polymorphism of GFI1 (rs34631763) generates a protein with an asparagine (N) instead of a serine (S) at position 36 (GFI1 36N ) and has a prevalence of 3%-5% among Caucasians.</s><s>Because GFI1 regulates myeloid development, we examined the role of GFI1 36N on the course of MDS disease.</s><s>To this end, we determined allele frequencies of GFI1 36N in four independent MDS cohorts from the Netherlands and Belgium, Germany, the ICGC consortium, and the United States.</s><s>The GFI1 36N allele frequency in the 723 MDS patients genotyped ranged between 9% and 12%.</s><s>GFI1 36N was an independent adverse prognostic factor for overall survival, acute myeloid leukemia-free survival, and event-free survival in a univariate analysis.</s><s>After adjustment for age, bone marrow blast percentage, IPSS score, mutational status, and cytogenetic findings, GFI1 36N remained an independent adverse prognostic marker.</s><s>GFI1 36S homozygous patients exhibited a sustained response to treatment with hypomethylating agents, whereas GFI1 36N patients had a poor sustained response to this therapy.</s><s>Because allele status of GFI1 36N is readily determined using basic molecular techniques, we propose inclusion of GFI1 36N status in future prospective studies for MDS patients to better predict prognosis and guide therapeutic decisions.</s><s>Copyright Ó 2016 ISEH -International Society for Experimental Hematology.</s><s>Published by Elsevier Inc.</s><s>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</s></p><p><s>GFI1 is a zinc finger transcriptional repressor that recruits histone-modifying enzymes, such as histone deacetylases, to the loci of its target genes <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</s><s>GFI1 regulates the functions of hematopoietic stem cells (HSCs) <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b2">3]</ref> as well as myeloid-lymphoid lineage decisions <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>.</s><s>A variant form of the GFI1 gene (denominated GFI1 36N ) is associated with a predisposition to develop de novo acute myeloid leukemia (AML) <ref type="bibr" target="#b5">[6]</ref>, but it has also been reported to be involved in a case of neutropenia <ref type="bibr" target="#b6">[7]</ref>.</s><s>Taking into consideration the predisposing role of GFI1 36N to de novo AML and its role in myeloid development, we investigated the role of GFI1 36N in myelodysplastic syndrome (MDS).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient cohort</head><p><s>All patient samples (peripheral blood [PB] or bone marrow [BM] aspirates) were obtained with informed consent according to the Declaration of Helsinki.</s><s>The respective local ethics committees approved the use of all patient samples.</s></p><p><s>The clinical characteristics of patients with a confirmed diagnosis of MDS used in this study have been previously described <ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref>.</s><s>Events in ''event-free survival'' were defined as death from any cause or progression of MDS to AML with blast counts higher than 20%.</s><s>Overall survival events are defined as death from any cause.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bone marrow morphology and cytopenia classification</head><p><s>Bone marrow morphology studies were performed at individual centers.</s><s>MDS was classified based on the World Health Organization (WHO) definition <ref type="bibr" target="#b13">[14]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Genotyping</head><p><s>Genotyping was performed according to published procedures <ref type="bibr" target="#b5">[6]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical methods</head><p><s>Significance of differences in percentages was determined using the two-sided, two-sample t test.</s><s>Survival of the different human cohorts is based on the presence of GFI1 36N univariate analysis using Kaplan-Meier survival methods.</s><s>Differences were assessed using the log-rank (Mantel-Cox) test.</s><s>We used Cox proportional-hazards regression modeling to determine the influence of different factors with respect to survival.</s><s>Factors taken into account were International Prognostic Scoring System (IPSS) risk group, BM blast count, age, sex, cytogenetic findings (based on IPSS classification), and in a last step, presence of GFI1 36N .</s><s>Analyses were performed either separately (with each factor analyzed independently) or with the presence or absence of GFI1 36N .</s><s>All p values reported are two-sided.</s><s>Because of the exploratory nature of this study, no adjustment for multiple testing was done.</s><s>All analyses presented were performed using GraphPad Prism 6 software (GraphPad Software, La Jolla, CA) or SPSS Version 19 (IBM, Armonk, NY).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Between 9% and 12% of all adult MDS patients in four different Caucasian cohorts from Europe and the United States <ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref> were heterozygous for GFI1 36N , and only two patients from the European cohorts (and none of the U.S. cohort) were homozygous for GFI1 36N (Table <ref type="table" target="#tab_0">1</ref>).</s><s>GFI1 36N allele frequency was higher among MDS patients than among the control cohort (3%-5%) as reported in our previous study regarding the role of GFI1 36N in de novo AML <ref type="bibr" target="#b14">[15]</ref>.</s><s>Although we did not determine the frequency of GFI1 36N among sex-and age-matched control subjects from every region, it is possible that GFI1 36N predisposes to MDS, similar to its predisposing role in de novo AML <ref type="bibr" target="#b14">[15]</ref>.</s></p><p><s>We analyzed the effect of GFI1 36N on MDS disease course in two independent cohorts.</s><s>Patients were recruited and treated either in the United States or in Europe.</s><s>The European cohorts consisted of patients recruited and treated at different centers in Germany, Belgium, and The Netherlands <ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref>.</s><s>The U.S. cohorts were referred to the Cleveland Clinic.</s></p><p><s>In the two MDS cohorts from Europe and the United States, presence of GFI1 36N was associated with an inferior event-free survival rate (Fig. <ref type="figure">1A, B</ref>).</s><s>GFI1 36N also had a negative impact on overall survival (Fig. <ref type="figure">1C, D</ref>) and on AML-free survival (data not shown).</s></p><p><s>Next, we examined the association between GFI1 36N and established prognostic factors.</s><s>GFI1 36N carriers were older, exhibited a tendency toward higher BM blast counts at diagnosis, were diagnosed with a more advanced stage of the disease according to histologic parameters, and had more adverse cytogenetic findings (Table <ref type="table" target="#tab_0">1</ref>).</s><s>With respect to key blood parameters, no other differences between GFI1 36N and GFI1 36S carriers were observed (Table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>American and European GFI1 36S homozygous patients had median follow-ups of 1,100 and 975 days, respectively.</s><s>American and European GFI1 36N carriers had median follow-ups of 540 and 350 days, respectively.</s><s>To gain more statistical power and to perform more specific analysis, we combined the U.S. and European cohorts.</s><s>One approach used to predict outcome of MDS patients is based on IPSS <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b16">17]</ref>.</s><s>A recently introduced, revised version of IPSS (denominated IPSS-R) distinguishes between more subclasses based on cytogenetic findings and cytopenic lineages <ref type="bibr" target="#b15">[16]</ref>.</s><s>However, not all of the specific data for determining IPSS-R status were present in our databases.</s><s>Therefore, we focused our examination on the nonrevised version of IPSS.</s></p><p><s>As reported previously <ref type="bibr" target="#b16">[17]</ref>, IPSS scoring predicted event-free outcome of GFI1 36S homozygous patients (Fig. <ref type="figure">1E</ref>).</s><s>On the basis of the same scoring system, GFI1 36N carriers had a significantly shorter event-free survival (Fig. <ref type="figure">1F</ref>).</s><s>Especially among MDS patients in the low-risk groups (groups low and intermediate 1 based on IPSS), GFI1 36N carriers had a much shorter event-free (Fig. <ref type="figure">1G</ref>) and AML-free survival (data not shown) than GFI1 36S homozygous patients.</s><s>We also examined the association between allele status, cytogenetic findings and event-free survival.</s><s>Similarly, presence of GFI1 36N was associated with an inferior outcome, independent of the cytogenetic finding (Table <ref type="table" target="#tab_0">1</ref>).</s><s>After stratification for cytogenetic risk groups (''low'' as one group and ''intermediate and high'' as a second group), the presence of a GFI1 36N allele was again linked to inferior event-free survival (Fig. <ref type="figure">1H, I</ref>) in both comparisons.</s></p><p><s>MDS patients with somatic mutations within EZH2 or ASXL1 have an inferior prognosis <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b18">19]</ref> (Fig. <ref type="figure" target="#fig_2">2A, B</ref>).</s><s>Presence of GFI1 36N in the absence of ASXL1 or EZH2 mutations had a similar effect on event-free survival as the presence of ASXL1 or EZH2 mutations (Fig. <ref type="figure" target="#fig_2">2C,  D</ref>).</s><s>Furthermore, the combined presence of a mutated form of either ASXL1 or EZH2 and a GFI1 36N allele had an additional adverse effect on event-free survival (Fig. <ref type="figure" target="#fig_2">2C, D</ref>).</s><s>Similar analyses were not possible for mutations of P53 or RUNX1 <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b18">19]</ref>, because of the small number of cases with P53 or RUNX1 mutation and GFI1 36N .</s></p><p><s>Because MDS patients who are hetero-or homozygous for GFI1 36N tend to be older at diagnosis, have more frequent adverse cytogenetic findings, and have a higher blast cell count at diagnosis, we examined whether the presence of GFI1 36N represents an adverse prognostic factor after adjusting for these findings.</s><s>We found that GFI1 36N was an independent marker after adjusting for the variables IPSS score, cytogenetic findings, and age, either alone or in combination (Supplementary Tables <ref type="table" target="#tab_0">E1 and E2</ref>, online only, available at www.exphem.org).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>One possible explanation why GFI1 36N accelerates AML development in MDS patients could be based on our findings using murine models.</s><s>We previously generated mice expressing GFI1 36N or GFI1 36S instead of murine Gfi1 <ref type="bibr" target="#b14">[15]</ref>.</s><s>We reported that GFI1 36N is not able to bind to its target genes to the same extent as the more common ''wild-type'' GFI1 36S variant.</s><s>Hence, presence of one allele of GFI1 36N led to higher genomewide levels of acetylated histone 3 at lysine 9 (H3K9) at Gfi1 target genes.</s><s>This led to active expression of genes favoring development of myeloid malignancies <ref type="bibr" target="#b14">[15]</ref>, which could explain how GFI1 36N accelerates both AML development and MDS-AML progression.</s><s>We recently reported that a low level of GFI1 expression, which might mimic the presence of GFI1 36N on a functional level, accelerates AML progression in different murine models of AML, including one model of MDS <ref type="bibr" target="#b19">[20]</ref>.</s><s>It is not yet clear why altering one amino acid changes the function of GFI1, and initial experiments regarding expression level, stability, ability to induce apoptosis, or interaction with histone deacetylases (HDACs) or lysine-specific demethylase 1 (LSD1) did not reveal any significant differences between GFI1 36N and GFI1 36S <ref type="bibr" target="#b14">[15]</ref> (unpublished data).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>=</head><p><s>We also examined whether GFI1 36N could predict response to therapy.</s><s>To explore this in more detail, we focused on patients that were treated with 5-azacitidine.</s><s>This treatment is used for patients who are otherwise not fit for allogeneic bone marrow transplantation or as a bridging to a definitive therapy <ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref>.</s><s>There was no difference between GFI1 36N heterozygous carriers and GFI1 36S patients achieving response to treatment with 5-azacytidine (51% of GFI1 36S homozygous carriers compared with 52% of GFI1 36N carriers).</s><s>However, the response to treatment was much shorter in GFI1 36N carriers than in GFI1 36S homozygous carriers (Fig. <ref type="figure" target="#fig_2">2E</ref>).</s><s>This observation is not surprising because treatment with hypomethylating agents, such as 5-azacitidine, would not revert the increased levels of H3K9 acetylation and H3K4 methylation seen in cells with a GFI1 36N allele <ref type="bibr" target="#b14">[15]</ref>.</s></p><p><s>The suitability of GFI1 36N as a prognostic marker should be verified in prospective studies and, if the findings can be confirmed, the status of GFI1 36N should be determined routinely in MDS patients.</s><s>Considering the role of GFI1 in myeloid development, GFI1 36N status could also be of prognostic value for patients with myeloproliferative diseases and chronic myeloid leukemia.</s><s>Indeed, the frequency of GFI1 36N is also elevated among patients with chronic myeloid  leukemia.</s><s>In summary, GFI1 36N could be a useful therapeutic and prognostic marker for myeloid malignancies.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>IPSS-low and int- 1 GFigure 1 .</head><label>11</label><figDesc><div><p><s>Figure 1.</s><s>Correlation between GFI136N and disease course of patients with MDS.</s><s>(A) Patients from different European cohorts diagnosed with MDS on the basis of WHO criteria were genotyped with respect to the presence of GFI1 36N and examined with respect to median event-free survival (see also Methods); 95% confidence interval (CI) 5 1.6-5.6.</s><s>Median survival is indicated.</s><s>(B) MDS Patients from a U.S. cohort diagnosed with MDS on the basis of WHO criteria were genotyped with respect to the presence of GFI136N and examined with respect to median event-free survival; 95% CI 5 1.7-7.2.</s><s>Median survival is indicated.</s><s>(C) The same cohorts as in (A) were examined with respect to overall survival (death of any cause); 95% CI 5 1.0-3.9.</s><s>Median survival is indicated.</s><s>(D) The same cohort as in (B) was examined with respect to overall survival (death from any cause) 95% CI 5 1.5-5.8.</s><s>Median survival is indicated.</s><s>(E) Event-free survival of GFI1 36S homozygous patients was stratified based on IPSS classification.</s><s>No sufficient follow-up was available for the International Cancer Genome Consortium (ICGC) patients.</s><s>Follow-up is based on the patient cohorts from the United States, the Netherlands, Belgium, and Germany.</s><s>Median survival is indicated.</s><s>(F) Event-free survival of GFI1 36N homozygous or heterozygous patients was stratified based on IPSS classification.</s><s>No sufficient follow up was available for the ICGC patients.</s><s>Follow-up is based on the patient cohorts from the United States, the Netherlands, Belgium, and Germany.</s><s>Median survival is indicated.</s><s>(G) Event-free survival of patients (shown in A) classified as either IPSS subtype low or intermediate 1 (int-1) was stratified with respect to the presence of GFI1 36N ; 95% CI 5 1.4-6.2.</s><s>(H) Patients from the U.S. and European cohorts with cytogenetic risk characteristics belonging to subtype ''low'' were stratified by the presence of GFI1 36N with respect to event-free survival; 95% CI 5 1.5-5.7.</s><s>Median survival is indicated.</s><s>(I) Patients from the U.S. and European cohorts with cytogenetic risk characteristics belonging to subtype ''intermediate'' or ''high'' were stratified by presence of GFI1 36N with respect to event-free survival; 95% CI 5 3.3-23.3.</s><s>Median survival is indicated.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Association between GFI1 36N , mutational status, prognosis, and therapeutic response.</s><s>(A) Median event-free survival of patients based on mutational status of ASXL1; 95% confidence interval (CI) 5 1.5-5.7.</s><s>(B) Median event-free survival of patients based on mutational status of EZH2; 95% CI 5 3.4-23.3.</s><s>(C) Median event-free survival of patients based on presence of GFI1 36N and mutational status of ASXL1.</s><s>(D) Median event-free survival of patients based on presence of GFI1 36N and mutational status of EZH2.</s><s>(E) From the cohorts of patients treated in Europe and the United States, patients treated with 5-azacitidine were stratified with respect to GFI1 status.</s><s>Presence of GFI1 36N was associated with a shorter response.</s><s>Median survival is indicated; 95% CI 5 1.1-10.5.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Features of GFI1 36N -and GFI1 36S -carrying adult MDS patients a</s></p></div></figDesc><table><row><cell></cell><cell>GFI1 36N (homo</cell><cell></cell><cell></cell></row><row><cell></cell><cell>[2 patients]-or</cell><cell>GFI1 36S</cell><cell></cell></row><row><cell></cell><cell>heterozygous)</cell><cell>(homozygozus)</cell><cell>P value</cell></row><row><cell>% All countries</cell><cell>10 (n 5 75)</cell><cell>90 (n 5 648)</cell><cell></cell></row><row><cell>% United States</cell><cell>11 (n 5 30)</cell><cell>89 (n 5 254)</cell><cell></cell></row><row><cell>% Germany</cell><cell>9 (n 5 20)</cell><cell>91 (n 5 193)</cell><cell></cell></row><row><cell>% Netherlands</cell><cell>12 (n 5 11)</cell><cell>88 (n 5 84)</cell><cell></cell></row><row><cell>and Belgium</cell><cell></cell><cell></cell><cell></cell></row><row><cell>% ICGC</cell><cell>11 (n 5 14)</cell><cell>89 (n 5 117)</cell><cell></cell></row><row><cell>Mean age</cell><cell cols="3">66 6 1.5 (n 5 73) 62 6 0.6 (n 5 638) 0.01</cell></row><row><cell>Gender (% male)</cell><cell>64 (n 5 47)</cell><cell cols="2">66 (n 5 426) 0.7</cell></row><row><cell>Blast percentage</cell><cell cols="3">9.4 6 0.3 (n 5 48) 6.7 6 1.1 (n 5 464) 0.01</cell></row><row><cell>(BM) WHO</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Hemoglobin</cell><cell cols="3">8.4 6 0.5 (n 5 24) 8.1 6 0.1 (n 5 191) 0.57</cell></row><row><cell>(mg/dL)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Platelet count</cell><cell cols="3">186 6 37 (n 5 24) 177 6 11 (n 5 195) 0.8</cell></row><row><cell>(1/nL)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Neutrophil count</cell><cell cols="3">2.8 6 0.8 (n 5 24) 2.7 6 0.2 (n 5 196) 0.9</cell></row><row><cell>(1/nL)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cytogenetic low</cell><cell>46 (n 5 27)</cell><cell cols="2">62 (n 5 246) 0.03</cell></row><row><cell>risk (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cytogenetic</cell><cell>14 (n 5 8)</cell><cell>16 (n 5 64)</cell><cell>0.5</cell></row><row><cell>intermediate</cell><cell></cell><cell></cell><cell></cell></row><row><cell>risk (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cytogenetic high</cell><cell>41 (n 5 24)</cell><cell>24 (n 5 96)</cell><cell>0.006</cell></row><row><cell>risk (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>IPSS low (%)</cell><cell>25 (n 5 13)</cell><cell cols="2">25 (n 5 127) 0.7</cell></row><row><cell>IPSS intermediate</cell><cell>40 (n 5 38)</cell><cell cols="2">42 (n 5 323) 0.7</cell></row><row><cell>1 (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>IPSS intermediate</cell><cell>21 (n 5 11)</cell><cell cols="2">21 (n 5 109) 0.7</cell></row><row><cell>2 (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>IPSS high (%)</cell><cell>15 (n 5 8)</cell><cell>10 (n 5 52)</cell><cell>0.25</cell></row><row><cell>5q-(%)</cell><cell>5 (n 5 2)</cell><cell>4 (n 5 13)</cell><cell>0.8</cell></row><row><cell>RA (%)</cell><cell>0 (n 5 0)</cell><cell>9 (n 5 30)</cell><cell>0.054</cell></row><row><cell>RARSþ RARST</cell><cell>11 (n 5 4)</cell><cell>9 (n 5 28)</cell><cell>0.7</cell></row><row><cell>(%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>RAEB-1 (%)</cell><cell>22 (n 5 8)</cell><cell>18 (n 5 59)</cell><cell>0.65</cell></row><row><cell>RAEB-2 (%)</cell><cell>39 (n 5 15)</cell><cell>22 (n 5 69)</cell><cell>0.02</cell></row><row><cell>RAEB-1 þ</cell><cell>61 (23)</cell><cell>40 (128)</cell><cell>0.01</cell></row><row><cell>RAEB-2 (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>RCMD (%)</cell><cell>24 (n 5 9)</cell><cell cols="2">38 (n 5 123) 0.09</cell></row><row><cell>MDS-u (%)</cell><cell>0</cell><cell>1 (n 5 4)</cell><cell>0.5</cell></row><row><cell cols="4">BM 5 bone marrow; ICGC 5 International Cancer Genome Consortium;</cell></row><row><cell cols="2">WHO 5 World Health Organization.</cell><cell></cell><cell></cell></row><row><cell cols="4">a GFI1 36N includes patients who are either homozygous or heterozygous</cell></row><row><cell cols="4">for GFI1 36N and, thus, carrying one GFI1 36S allele. GFI1 36S refers to pa-</cell></row><row><cell cols="4">tients homozygous for GFI1 36S . Cytogenetic low risk: normal karyotype,</cell></row><row><cell cols="4">5q-, 20q-, -Y; poor risk: complex aberrations ($3 anomalies), chromo-</cell></row><row><cell cols="4">some 7 anomalies; intermediate risk: all other aberrations. IPSS was</cell></row><row><cell cols="4">based on Greenberg et al. [17]. Refractory anemia (RA), refractory</cell></row><row><cell cols="4">anemia with ring sideroblasts (RARS), refractory anemia with excess</cell></row><row><cell cols="4">blasts, type 1 (RAEB-1), refractory anemia with excess blasts, type 2</cell></row><row><cell cols="4">(RAEB-2), refractory cytopenia with multilineage dysplasia (RCMD),</cell></row><row><cell cols="4">and MDS-unclassified (MDS-u) are based on the WHO definition for</cell></row><row><cell cols="4">MDS. Standard errors of mean are given. Data for IPPS and cytogenetic</cell></row><row><cell cols="4">classification are missing due to the lack of cytogenetic information on</cell></row></table><note><p><s>patients at the time of diagnosis.</s><s>Data for histologic classification are missing because of the missing specification of MDS according to WHO criteria.</s><s>The missing patients were diagnosed as having MDS according to the WHO definition.</s><s>Student's t test was used to determine the significance of values, and two-sample t tests were used to determine the significance of differences between percentages.</s><s>The different cohorts were independent of each other.</s><s>No overlap exists with respect to samples.</s><s>The numbers in parentheses correspond to the absolute numbers related to the indicated percentages.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">L. Botezatu et al./ Experimental Hematology 2016;44:590-595</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>CK was supported by a Max Eder Grant from the Deutsche Krebshilfe, Germany, and the IFORES fellowship from the University Clinic Essen, Germany.</s><s>TM's lab was supported by a grant from the Leukemia and Lymphoma Society (USA).</s><s>TM holds a Tier 1 Canada Research Chair and grants from the Canadian Institutes of Health Research (CIHR, Grants MOP-84238 and MOP-111011).</s><s>JB and AP are supported by Bloodwise (UK).</s></p><p><s>We thank the patients for their consent to participate in the different studies and Saskia Grunwald and Renata K€ oster for excellent technical assistance.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest disclosure</head><p><s>Cyrus Khandanpour received travel reimbursement from Amgen and Chugai for attending scientific conferences.</s><s>Jaroslaw Maciejewski received speaker honoraria from Celgene and Alexion.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Gfi1-cells and circuits: Unraveling transcriptional networks of development and disease</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Phelan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Shroyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gebelein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Grimes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Hematol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="300" to="307" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Gfi1 and Gfi1b: Key regulators of hematopoiesis</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Vvan Der Meer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Jansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Van Der Reijden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1834" to="1843" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Gfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem cells</title>
		<author>
			<persName><forename type="first">H</forename><surname>Hock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Hamblen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Rooke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">431</biblScope>
			<biblScope unit="page" from="1002" to="1007" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Person</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">Q</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Duan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="308" to="312" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Gfi1 integrates progenitor versus granulocytic transcriptional programming</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Horman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Velu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chaubey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="5466" to="5475" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">A variant allele of growth factor independence 1 (GFI1) is associated with acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">C</forename><surname>Khandanpour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thiede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Valk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="2462" to="2472" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">Mosaic tetraploidy and transient GFI1 mutation in a patient with severe chronic neutropenia. Pediatr Blood Cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Hochberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Miron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">N</forename><surname>Hay</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008</date>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="630" to="632" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Somatic SETBP1 mutations in myeloid malignancies</title>
		<author>
			<persName><forename type="first">H</forename><surname>Makishima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Nguyen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="942" to="946" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Acquired mutations in TET2 are common in myelodysplastic syndromes</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Langemeijer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Kuiper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Berends</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="838" to="842" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Clinical and biological implications of driver mutations in myelodysplastic syndromes</title>
		<author>
			<persName><forename type="first">E</forename><surname>Papaemmanuil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gerstung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Malcovati</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page">3699</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study</title>
		<author>
			<persName><forename type="first">U</forename><surname>Germing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lauseker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hildebrandt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1286" to="1292" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients</title>
		<author>
			<persName><forename type="first">U</forename><surname>Platzbecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Al-Ali</forename><surname>Hk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Gattermann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="696" to="698" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge</title>
		<author>
			<persName><forename type="first">J</forename><surname>Schanz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tuchler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sole</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="820" to="829" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Jaffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Diebold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="3835" to="3849" />
			<date type="published" when="1997-11">November 1997. 1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">The human GFI136N variant induces epigenetic changes at the Hoxa9 locus and accelerates K-RAS driven myeloproliferative disorder in mice</title>
		<author>
			<persName><forename type="first">C</forename><surname>Khandanpour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Krongold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schutte</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="4006" to="4017" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Revised international prognostic scoring system for myelodysplastic syndromes</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Greenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tuechler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schanz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="2454" to="2465" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">International scoring system for evaluating prognosis in myelodysplastic syndromes</title>
		<author>
			<persName><forename type="first">P</forename><surname>Greenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Lebeau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="2079" to="2088" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Clinical effect of point mutations in myelodysplastic syndromes</title>
		<author>
			<persName><forename type="first">R</forename><surname>Bejar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stevenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Abdel</forename><forename type="middle">-</forename><surname>Wahab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="page" from="2496" to="2506" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes</title>
		<author>
			<persName><forename type="first">R</forename><surname>Bejar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Stevenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Caughey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="3376" to="3382" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">GFI1 as a novel prognostic and therapeutic factor for AML/MDS</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Hones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Botezatu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Helness</surname></persName>
		</author>
		<idno type="DOI">10.1038/leu.2016.11</idno>
		<ptr target="http://dx.doi.org/10.1038/leu.2016.11" />
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Saunthararajah</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hematol Am Soc Hematol Educ Program</title>
		<imprint>
			<biblScope unit="volume">2013</biblScope>
			<biblScope unit="page" from="511" to="521" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Recent developments in myelodysplastic syndromes</title>
		<author>
			<persName><forename type="first">R</forename><surname>Bejar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Steensma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="2793" to="2803" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">How we treat higher-risk myelodysplastic syndromes</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Sekeres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cutler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="829" to="836" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
